Pfizer secures European approval for Avastin biosimilar 19-Feb-2019 By Ben Hargreaves Pfizer’s Zirabev receives approval from the European Commission as a biosimilar to Roche’s Avastin, which brought in sales of CHF1.8bn in Europe during 2018.